Form 4: NextCure Director Anne Borgman Acquires 18,700 Stock Options

NextCure, Inc. Director Anne Elizabeth Borgman has acquired 18,700 stock options with an exercise price of $0.47, vesting by June 2026.

Summary

• Anne Elizabeth Borgman, a Director at NextCure, Inc. (NXTC), acquired 18,700 stock options on June 20, 2025.
• The acquired options have an exercise price of $0.47 per share.
• These options are scheduled to vest in full on the earlier of June 20, 2026, or the date of the 2026 Annual Meeting of Stockholders.
• The stock options have an expiration date of June 19, 2035.
• Following this transaction, Ms. Borgman beneficially owns 18,700 derivative securities directly.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally viewed positively as it indicates insider confidence in the company's future prospects and aligns their interests with shareholders. The low exercise price also suggests potential for future upside.

Positives

• The acquisition of 18,700 stock options by Director Anne Elizabeth Borgman signals insider confidence in NextCure, Inc.'s future prospects.
• The exercise price of $0.47 per share is relatively low, offering significant potential upside if the company's stock price appreciates.

Negatives

• No explicit negatives are detailed in this Form 4 filing, which primarily reports insider transactions.

Risks

• The value of the acquired stock options is contingent upon NextCure, Inc.'s common stock price exceeding the $0.47 exercise price; if the stock price remains below this level, the options may not be profitable.
• The options are subject to a vesting schedule, meaning they are not immediately exercisable, tying their potential value to future company performance and Ms. Borgman's continued service.

Future Outlook

This Form 4 filing primarily reports an insider transaction and does not contain explicit forward-looking statements or guidance from NextCure, Inc. However, the acquisition of stock options by a director can be interpreted as a positive signal regarding future expectations for the company's performance.

Industry Context

This filing is a routine insider transaction report common in publicly traded companies, particularly in the biotechnology or pharmaceutical sector where equity compensation, such as stock options, is a standard component of director remuneration. Such grants are designed to align the interests of directors with long-term shareholder value.

Comparison to Industry Standards

• The grant of stock options to a director is a common practice in the biotechnology industry, aligning executive and board interests with shareholder returns. While specific comparable grants from other companies are not detailed in this filing, the structure of the option grant (exercise price, vesting schedule, expiration) is consistent with typical equity compensation plans for directors in similar-sized biotech firms.

Stakeholder Impact

• Shareholders: The acquisition of options by a director may be perceived as a positive indicator of confidence in the company's future, potentially influencing investor sentiment and stock valuation.

Next Steps

• The acquired stock options will vest on the earlier of June 20, 2026, or the 2026 Annual Meeting of Stockholders.
• The options can be exercised at any time after vesting until their expiration on June 19, 2035.

Key Dates

Keywords

NextCure, NXTC, Stock Options, Insider Trading, Form 4, Director, Equity Compensation, Beneficial Ownership